The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 1.84
Ask: 1.96
Change: -0.14 (-6.86%)
Spread: 0.12 (6.522%)
Open: 2.00
High: 2.01
Low: 2.00
Prev. Close: 2.04
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Feb 2017 14:04

RNS Number : 2167X
Immupharma PLC
17 February 2017
 

17 FEBRUARY 2017

 

 

 

NOTIFICATION OF INTEREST BY LEGAL & GENERAL

 

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Legal & General Group Plc ("L&G") confirming its holding in ImmuPharma of 3,774,714 million Ordinary Shares in the capital of the Company.

 

Full disclosure of the TR1 is shown below:

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

ImmuPharma Plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc (L&G)

4. Full name of shareholder(s)  (if different from 3.):

Legal & General Assurance Society Limited (LGAS)

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

15 February 2017

6. Date on which issuer notified:

16 February 2017

7. Threshold(s) that is/are crossed orreached:

 

L&G (Below 3%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD GBP 0.10

3,774,714

 Below 3%

 Below 3%

-

Below 3%

-

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

 Below 3%

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( Below 5% = Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( Below 5% = Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( Below 5% = Total Position)

Legal & General Group Plc (Direct) (L&G) ( Below 3% = LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS & LGPL)

Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of  124,638,362

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

 

 

 

 

 

-Ends-

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

Northland Capital Partners Limited (NOMAD & Broker)

Patrick Claridge, David Hignell, Michael Mackintosh, Corporate Finance

Rob Rees, Corporate Broking

+44 (0)20 3861 6625

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLZDLFFDLFBBBF
Date   Source Headline
19th May 20107:01 amRNSInitiation Of Phase I/IIA Studies In Cancer
19th May 20107:00 amRNSPreliminary Results
8th Apr 20109:26 amRNSBest Drug Development Company in Europe Award
5th Jan 20103:00 pmRNSAdditional Listing
5th Jan 20107:00 amRNSING take 4% stake in ImmuPharma plc
3rd Dec 20097:00 amRNSR&D Symposium at the CNRS in Paris
19th Nov 20097:00 amRNSPositive Final Lupuzor Trial Results
19th Oct 200910:31 amRNS'Best Technology 2009' Award at the AIM Awards
9th Oct 200910:14 amRNSAppointment of Joint Broker
29th Sep 20097:00 amRNSInterim Results
21st Sep 20099:55 amRNS8th Annual Bio Investor Forum
17th Sep 20097:00 amRNSJMP Healthcare Focus Conference
24th Jul 200912:12 pmRNSResult of AGM
23rd Jul 20094:17 pmRNSDirectors' Dealings
30th Jun 20097:00 amRNSAnnual Report and Accounts
24th Jun 20097:00 amRNSPreliminary Results
17th Jun 20097:00 amRNSPiper Jaffray Europe Conference
23rd Mar 20097:00 amRNSDirectors' Dealings
4th Feb 200912:32 pmRNSShare Options
2nd Feb 20092:33 pmRNSCephalon license exercise
30th Jan 20097:00 amRNSSuccessful trial results
22nd Dec 200812:00 pmRNSfurther instalment of grant
25th Nov 20087:00 amRNSOption Agreement with Cephalon
12th Nov 20087:00 amRNSGrant Award
21st Oct 20089:31 amRNSPatents Granted
17th Oct 20084:22 pmRNSAdditional Listing and Total Voting Rights
25th Sep 20087:00 amRNSInterim Results
5th Aug 20083:44 pmRNSAGM Result
10th Jul 20087:00 amRNSSecond Placing
2nd Jul 20087:30 amRNSToxicology study
2nd Jul 20087:00 amRNSFund Raising
30th Jun 20083:00 pmRNSAnnual Report and Accounts
20th May 20087:00 amRNSPre-clinical Data
13th May 20086:00 amRNSTrademark Approval
8th May 20087:00 amRNSPreliminary Results
26th Feb 20087:00 amRNSPhase IIb Trial of IPP-201101
8th Jan 20087:00 amRNSNovel Drug Candidate
18th Dec 200712:51 pmRNSDirectors' Dealings
6th Dec 20077:01 amRNSInitiation of Phase IIb trial
16th Nov 200712:28 pmRNSAppointment of Nomad
28th Sep 20077:02 amRNSInterim Results
22nd Aug 20077:00 amRNSCompound Discovery
20th Aug 200710:17 amRNSAIM Rule 26
13th Aug 20074:17 pmRNSDirectors' Dealing
6th Aug 20072:40 pmRNSGrant of Options
10th Jul 20077:01 amRNSPivotal phase II/III trial
13th Jun 20072:00 pmRNSAGM and Board Update
1st May 20077:02 amRNSPreliminary Results
27th Apr 20074:02 pmRNSBoard Appointment
15th Feb 20077:01 amRNSAppointment of adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.